panitumumab
- Generic Name
- panitumumab
- Brand Names
- Vectibix
- Drug Type
- Biotech
- CAS Number
- 339177-26-3
- Unique Ingredient Identifier
- 6A901E312A
Overview
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.
Background
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.
Indication
美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。
Associated Conditions
- Metastatic Colorectal Cancer (CRC)
Clinical Trials
FDA Approved Products
Vectibix
Manufacturer:Amgen Inc
Route:INTRAVENOUS
Strength:400 mg in 20 mL
Approved: 2021/08/25
NDC:55513-956
Vectibix
Manufacturer:Amgen Inc
Route:INTRAVENOUS
Strength:100 mg in 5 mL
Approved: 2021/08/25
NDC:55513-954
Singapore Approved Products
Vectibix Concentrate for Solution for Infusion 100 mg/vial
Manufacturer:Amgen Manufacturing Limited
Form:INFUSION, SOLUTION CONCENTRATE
Strength:100 mg/vial
Online:Yes
Approved: 2014/01/27
Approval:SIN14498P
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath